Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy

Author(s):  Laque Larissa C, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C

Issue:  Jan/Feb 2019 - Volume 23, Number 1
View All Articles in Issue

Page(s):  77-81

Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 1
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 2
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 3
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 4
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy Page 5

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to evaluate the transmucosal permeation of progesterone and testosterone using Pentravan as its vehicle for vaginal delivery. Progesterone deficiency is a hormone imbalance that could lead to luteal-phase deficiency, which is a common problem in assisted reproductive technologies. Testosterone has been explored for treating postmenopausal symptoms, such as vaginal atrophy. The ex vivo experiments were performed using porcine vaginal mucosa and phosphate buffered saline + 0.5% 2-hydroxypropyl-ß-cyclodextrin as the receptor media, which was later quantified through high-performance liquid chromatography. The percentage of the permeated drug was 0.4% and 20.3% for progesterone and testosterone, respectively. The permeation studies revealed that testosterone formulated with Pentravan is potentially effective in reaching the bloodstream and acts locally, whereas progesterone was mostly retained in the mucosa.

Related Keywords: progesterone, testosterone, intravaginal administration, vaginal preparation, transmucosal permeation, vaginal atrophy, formulation, luteal phase deficiency, menopausal women, liposomal vehicle

Related Categories: FORMULATIONS, HRT, PEER-REVIEWED, DOSAGE FORMS/DRUG CARRIERS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Ex Vivo Evaluation of Intravaginal Progesterone and Testosterone to Treat the Luteal-phase Deficiency and Vaginal Atrophy
Laque Larissa C
, Raposo Nádia RB, Fernandes Brandão Marcos Antônio, de Oliveira Ferreira Anderson, Polonini Hudson C
Jan/Feb 2019
Pg. 77-81

Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome
Riepl Mike
Nov/Dec 2018
Pg. 456-465

Gentian Violet Vaginal Suppositories
Allen Loyd V Jr
Nov/Dec 2009
Pg. 556

Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
Jan/Feb 2024
Pg. 58

Estradiol 0.1% Vaginal Solution
Allen Loyd V Jr
Sep/Oct 2008
Pg. 450

Mupirocin 1% (20-mg) Vaginal Suppository
Allen Loyd V Jr
Jul/Aug 2009
Pg. 338

Vulvovaginal Symptoms in a Postmenopausal Woman: A Case Study
Lima Ramona
, Gonzalez Mark A, Urwin Craig, Jean Linda, Carvalho Maria, Banov Fabiana
Mar/Apr 2023
Pg. 108-112

Case Report of a Human Papillomavirus Infection Treated with Green Tea Extract and Curcumin Vaginal Compounded Medications
Agbi Kelechi E
, Hover Sara, Carvalho Maria
May/Jun 2018
Pg. 196-202

Nystatin 100,000-units Vaginal Inserts
Allen Loyd V Jr
Jul/Aug 2016
Pg. 322

Tri-Est, Progesterone, and Testosterone in Versatile, Phytobase, Fitaline, and HRT Supreme Cream Bases
Allen Loyd V Jr
May/Jun 2017
Pg. 238

Clindamycin 100-mg Vaginal Suppositories
Allen Loyd V Jr
Jul/Aug 2009
Pg. 334

Progesterone Vaginal Suppositories (Fatty Acid Base)
Allen Loyd V Jr
Jan/Feb 2024
Pg. 63

Progesterone 3% Vaginal Gel
Allen Loyd V Jr
Jan/Feb 1998
Pg. 58

Progesterone Vaginal Cream (5%)
Allen Loyd V Jr
Jan/Feb 1998
Pg. 64

Progesterone Vaginal Suppositories (Fatty Acid Base)
Allen Loyd V Jr
Jan/Feb 1998
Pg. 65

Progesterone Vaginal Suppositories (Polyethylene Glycol Bases)
Allen Loyd V Jr
Jan/Feb 1998
Pg. 66

Testosterone 1-mg/0.1-mL Topical Vaginal/Scrotal Spray
Allen Loyd V Jr
Nov/Dec 2000
Pg. 464

Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Polonini Hudson
, de Oliveira Ferreira Anderson, Dijkers Eli
Sep/Oct 2021
Pg. 422-426

Poster Presentation Report: Safety of Maternal Testosterone Therapy During Breast Feeding
Glaser Rebecca L
, Newman Mark, Parsons Melanie, Zava David, Glaser-Garbrick Daniel
Jul/Aug 2009
Pg. 314-317

Case Study: Absorption of Testosterone Cream via Scrotal Delivery
Needham Shawn
, Needham Shane
Nov/Dec 2018
Pg. 466-468

Return to Top